A Novel Treatment for Metastatic Melanoma

This study is currently recruiting participants.
Verified by Northwestern University, February 2010

First Received: June 23, 2008   Last Updated: February 12, 2010

Purpose

A novel treatment for metastatic melanoma combining a laser and an immune-system stimulating cream.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Intervention</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metastatic Melanoma</td>
<td>Other: Photoimmunotherapy</td>
<td>Phase I</td>
</tr>
</tbody>
</table>

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Official Title: In Situ Photoimmunotherapy: A Tumor Directed Treatment for Advanced Melanoma With Cutaneous Metastases

Further study details as provided by Northwestern University:

Primary Outcome Measures:

- Tolerability, safety, toxicity, of novel treatment through evaluation of subject response and physician observation of adverse events. [Time Frame: 24 weeks]
  [Designated as safety issue: Yes]

Secondary Outcome Measures:

- Assess time to disease progression [Time Frame: 24 weeks to years]
  [Designated as safety issue: No]
- Evaluate tumor response by measuring clinically apparent tumors throughout study. [Time Frame: 24 weeks] [Designated as safety issue: No]
- Quantify overall survival in this study population [Time Frame: years]
  [Designated as safety issue: No]
Estimated Enrollment: 15
Study Start Date: April 2008
Estimated Study Completion Date: April 2010
Estimated Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)

<table>
<thead>
<tr>
<th>Arms</th>
<th>Assigned Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1: Experimental</td>
<td>Other: Photoimmunotherapy</td>
</tr>
<tr>
<td></td>
<td>DIOMED laser + photosensitizing agent</td>
</tr>
<tr>
<td></td>
<td>injected intralesionally and topical</td>
</tr>
<tr>
<td></td>
<td>immuno-modulating cream</td>
</tr>
<tr>
<td></td>
<td>DIOMED laser + photosensitizing agent</td>
</tr>
<tr>
<td></td>
<td>injected intralesionally and topical</td>
</tr>
<tr>
<td></td>
<td>immuno-modulating cream</td>
</tr>
</tbody>
</table>

**Detailed Description:**

A novel treatment for metastatic melanoma combining a laser and an immune-system stimulating cream with or without injection of a substance that makes the tumor more sensitive to the laser.

**Eligibility**

**Ages Eligible for Study:** 18 Years and older
**Genders Eligible for Study:** Both
**Accepts Healthy Volunteers:** No

**Criteria**

**Inclusion Criteria:**

1. Age 18 and older
2. Subjects must have histologically confirmed cutaneous metastatic malignant melanoma from any tumor site.
3. Patients must have measurable disease. See section 8.2 for the evaluation of measurable disease (RECIST)
4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
5. Required laboratory parameters (all blood tests must be obtained within 14 days prior to the start of the study treatment):
   - Platelet count > 40,000 per mm3

**Exclusion Criteria:**

1. Life expectancy, in the opinion of the investigator of less than 4 months
2. Known allergy to any drugs used in treatment
3. Immunosuppression, including HIV positive subjects, use of systemic steroids daily or other immunosuppressive medications within 1 month of treatment
4. Chemotherapy/immunotherapy within 4 weeks of initiation
5. Local chemotherapy or immunotherapy to target lesions with 4 weeks of initiation
6. Radiation therapy at the treatment site within 4 weeks of initiation
7. Uncontrolled brain metastases
8. History of cutaneous photosensitization or photodermatoses
9. Non-treated, active cancers other than melanoma and non-melanoma skin cancers.
10. Active infectious disease requiring antibiotic therapy
11. Unstable medical illness
12. Past or present major psychiatric illness
13. Pregnant or lactating women

**Contacts and Locations**

http://clinicaltrials.gov/ct2/show/NCT00758797
Please refer to this study by its ClinicalTrials.gov identifier: NCT00758797

Contacts

Contact: Marcy Urbanich 312-695-6829 m-urbanich@northwestern.edu
Contact: Stephanie St. Pierre, MD 312-695-6786 s-stpierre@northwestern.edu

Locations

United States, Illinois

Northwestern University, Feinberg School of Medicine, Department of Dermatology

Chicago, Illinois, United States, 60611
Contact: Stephanie A St. Pierre, MD 312-695-6786 s-stpierre@northwestern.edu
Principal Investigator: Murad Alam, MD
Sub-Investigator: Timothy Kuzel, MD
Sub-Investigator: Mary Martini, MD
Sub-Investigator: Jeffrey Wayne, MD
Sub-Investigator: Simon S. Yoo, MD
Sub-Investigator: Misbah Khan, MD
Sub-Investigator: Stephanie A St. Pierre, MD

Sponsors and Collaborators

Northwestern University

Investigators

Principal Investigator: Murad Alam, MD Northwestern University

More Information

No publications provided

Responsible Party: Northwestern University ( Murad Alam, MD )
Study ID Numbers: MA-071008
Study First Received: June 23, 2008
Last Updated: February 12, 2010
ClinicalTrials.gov Identifier: NCT00758797 History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Northwestern University:
metastatic melanoma

Additional relevant MeSH terms:
Neuroectodermal Tumors Neoplasms, Nerve Tissue
Neoplasms Nevi and Melanomas
Neoplasms by Histologic Type Neuroendocrine Tumors
Neoplasms, Germ Cell and Embryonal Melanoma

ClinicalTrials.gov processed this record on February 28, 2010